Page 92 - Read Online

Sharma et al. Cancer Drug Resist 2023;6:688-708 https://dx.doi.org/10.20517/cdr.2023.82 Page 708

brain clearing. J Biophotonics 2018;11:e201700287. DOI PubMed
189. Tian T, Liang R, Erel-Akbaba G, et al. Immune checkpoint inhibition in GBM primed with radiation by engineered extracellular
vesicles. ACS Nano 2022;16:1940-53. DOI PubMed PMC
190. Sun T, Patil R, Galstyan A, et al. Blockade of a laminin-411-notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits
glioblastoma growth through tumor-microenvironment cross-talk. Cancer Res 2019;79:1239-51. DOI PubMed PMC
191. Quader S, Liu X, Toh K, et al. Supramolecularly enabled pH- triggered drug action at tumor microenvironment potentiates
nanomedicine efficacy against glioblastoma. Biomaterials 2021;267:120463. DOI
192. Fan R, Chen C, Mu M, et al. Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-
enhanced glioblastoma immunotherapy. ACS Nano 2023;17:9126-39. DOI
193. Kannappan V, Liu Y, Wang Z, et al. PLGA-nano-encapsulated disulfiram inhibits hypoxia-induced NF-κB, cancer stem cells, and
targets glioblastoma in vitro and in vivo. Mol Cancer Ther 2022;21:1273-84. DOI
194. Zou Y, Sun X, Yang Q, et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma
gene therapy. Sci Adv 2022;8:eabm8011. DOI PubMed PMC
195. Jiang Y, Zhang J, Meng F, Zhong Z. Apolipoprotein E peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency
targeted protein therapy for glioblastoma. ACS Nano 2018;12:11070-9. DOI
196. Okada M, Shimizu K, Fujii SI. Identification of neoantigens in cancer cells as targets for immunotherapy. Int J Mol Sci
2022;23:2594. DOI PubMed PMC
197. Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat
Rev Drug Discov 2022;21:261-82. DOI PubMed